{"id":"NCT04152200","sponsor":"Alnylam Pharmaceuticals","briefTitle":"A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1","officialTitle":"ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-21","primaryCompletion":"2021-05-18","completion":"2025-06-23","firstPosted":"2019-11-05","resultsPosted":"2022-07-12","lastUpdate":"2025-07-18"},"enrollment":21,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Hyperoxaluria Type 1","Primary Hyperoxaluria"],"interventions":[{"type":"DRUG","name":"Lumasiran","otherNames":["ALN-GO1","OXLUMO"]}],"arms":[{"label":"Lumasiran","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).","primaryOutcome":{"measure":"Cohort A: Percent Change in Plasma Oxalate From Baseline to Month 6","timeFrame":"Baseline to Month 6","effectByArm":[{"arm":"Cohort A: Lumasiran","deltaMin":-33.33,"sd":17.63}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":14,"countries":["United States","Australia","Belgium","France","Israel","Italy","Jordan","Lebanon","Netherlands","Turkey (TÃ¼rkiye)","United Arab Emirates"]},"refs":{"pmids":["35843439"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":6},"commonTop":["Pyrexia","Injection site reaction","Diarrhoea","Constipation","Device related infection"]}}